Patents Assigned to IMMUTRIX THERAPEUTICS, INC.
-
Patent number: 12005173Abstract: Systems and methods for the treatment of a bodily fluid, for example, using a cartridge that may include a cartridge body configured to retain an adsorptive material and an end segment configured to cover a first end of the cartridge body. The end segment may include a circular face comprising an outwardly truncated conical shape and defining an internal conical space, a cylindrical wall joined to a periphery of the circular face, and an inlet configured to provide fluid connection to a source of the bodily fluid. The inlet may be disposed tangential to the circular face at the cylindrical wall so as to direct bodily fluid entering the cartridge into the internal conical space tangentially so as to decelerate the bodily fluid within the internal conical space prior to contact with the adsorptive material disposed within the cartridge body.Type: GrantFiled: November 16, 2018Date of Patent: June 11, 2024Assignee: Immutrix Therapeutics, Inc.Inventors: Todd Goodrich, Ryan McGivern, Rob Moyers
-
Publication number: 20240165314Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: ApplicationFiled: December 26, 2023Publication date: May 23, 2024Applicant: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Publication number: 20240100090Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: ApplicationFiled: October 30, 2023Publication date: March 28, 2024Applicant: Immutrix Therapeutics, Inc.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 11918728Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: November 6, 2020Date of Patent: March 5, 2024Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller, Jose A. Diaz-Aunon
-
Patent number: 11896753Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: March 3, 2020Date of Patent: February 13, 2024Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 11839628Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: GrantFiled: March 26, 2021Date of Patent: December 12, 2023Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Publication number: 20230372596Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is in a range from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is in a range from about 0.1:100 to 100:0.1 to produce a third filtrate.Type: ApplicationFiled: August 3, 2023Publication date: November 23, 2023Applicant: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 11759561Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: September 1, 2020Date of Patent: September 19, 2023Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Publication number: 20220120648Abstract: Methods for quantifying an amount of exosomes in subject derived biological fluid and comparing to a control provides for a method of identifying a medical condition. Removing an amount of the exosomes by adsorption and binding of the exosomes to an absorbent material, and administering the reconstituted biological fluid comprising a reduced amount of exosomes back to the subject also provides for a method of treating the identified medical condition.Type: ApplicationFiled: October 17, 2019Publication date: April 21, 2022Applicant: IMMUTRIX THERAPEUTICS, INC.Inventors: Jose A. Diaz-Aunon, Oleta A. Sandiford, Pranela Rameshwar
-
Publication number: 20210236543Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: ApplicationFiled: March 26, 2021Publication date: August 5, 2021Applicant: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 10960022Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: GrantFiled: October 16, 2018Date of Patent: March 30, 2021Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Publication number: 20200397973Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: ApplicationFiled: September 1, 2020Publication date: December 24, 2020Applicant: ImMutriX Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 10773011Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: May 2, 2017Date of Patent: September 15, 2020Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 10617813Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: November 18, 2015Date of Patent: April 14, 2020Assignee: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 10137151Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: GrantFiled: April 17, 2015Date of Patent: November 27, 2018Assignee: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 9669151Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: March 9, 2015Date of Patent: June 6, 2017Assignee: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller